Skip to main content

Table 1 Patient baseline characteristics by HbA1c treatment target

From: Individualised treatment targets in patients with type-2 diabetes and hypertension

HbA1c target

≤ 6.5%

N = 2644

> 6.5 to ≤ 7.0%

N = 2912

> 7.0 to ≤ 7.5%

N = 1135

p value

Age (years)

63.3 ± 11.7

66.2 ± 10.5

66.3 ± 10.9

< 0.0001

Female gender (%)

46.3

45.7

44.2

0.51

Diabetes duration (years)

6.1 ± 5.3

7.4 ± 5.8

7.8 ± 6.0

< 0.0001

Bodyweight (kg)

90.2 ± 18.4

90.3 ± 18.4

91.0 ± 18.9

0.45

Any vascular disease (%)a

31.3

33.4

36.5

< 0.05

Any diabetes related disease (%)b

73.1

80.1

77.4

< 0.0001

Other concomitant disease (%)

41.8

47.1

50.8

< 0.0001

All BG values available (< 6 weeks)c

42.9

48.0

38.0

< 0.0001

Metformin (%)

79.9

81.7

81.2

0.23

Sulfonylurea (%)

15.1

19.1

22.5

< 0.0001

Glucosidase inhibitors (%)

1.0

1.5

1.0

0.18

Glinides (%)

2.4

4.0

5.7

< 0.0001

Glitazones (%)

0.5

0.7

0.3

0.18

DPP4-inhibitor (%)

60.0

66.2

63.9

< 0.0001

GLP1-analogue (%)

4.2

5.8

4.4

< 0.05

SGLT-2-inhibitor (%)

1.7

1.9

2.1

0.68

Any insulin (%)

10.9

18.8

22.2

< 0.0001

≥ 3 oral antidiabetic drugs (%)

7.1

11.8

14.0

< 0.0001

≥ 3 antihypertensive drugs (%)

34.4

37.7

37.2

< 0.05

Any non-severe hypoglycaemia (%)d

4.6

5.9

6.6

< 0.05

Any severe hypoglycaemia (%)e

0.9

0.6

0.3

0.05

PR body weight increase (%)

32.6

35.9

34.7

< 0.01

PR signs of hypoglycaemia (%)

14.9

12.8

14.7

0.66

Mean EQ-5D (mean ± SD)

0.90 ± 0.16

0.88 ± 0.17

0.86 ± 0.18

< 0.0001

Problems with mobility (%)

20.7

28.3

33.0

< 0.0001

Problems with self-care (%)

5.9

10.7

12.9

< 0.0001

Problems with daily activities (%)

15.3

25.4

28.8

< 0.0001

Any pain (%)

41.6

51.4

56.8

< 0.0001

Any anxiety/depression (%)

75.9

72.6

72.2

< 0.01

  1. HbA1c glycated haemoglobin, BG blood glucose, DPP dipeptidyl peptidase, GLP glucagon-like peptide, SGLT sodium-glucose transporter protein, PR patient-reported, EQ-5D EuroQol 5D questionnaire regarding health-related quality of life
  2. aAny of CAD, prior MI, prior PCI, prior CABG, prior stroke, prior diagnosis of HF
  3. bAny of neuropathy, retinopathy, laser coagulation, macular oedema, eye doctor visit, blindness, dialysis, or amputation
  4. cFasting blood glucose, postprandial blood glucose, and HbA1c available
  5. dWithout symptoms, symptoms but without help, with help—but not medical help or hospitalisation
  6. eSymptoms with need for medical help or hospital admission
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840